Stockscreener 앱 받기
2.76
1.10%
0.03
시간 외 거래:
2.77
0.01
+0.36%
전일 마감가:
$2.73
열려 있는:
$2.74
하루 거래량:
748.27K
Relative Volume:
0.98
시가총액:
$273.73M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-0.9356
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
-4.50%
1개월 성능:
-3.16%
6개월 성능:
+58.62%
1년 성능:
-3.83%
1일 변동 폭
$2.62
$2.79
1주일 범위
$2.59
$3.07
52주 변동 폭
$1.05
$3.97
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
2.76 | 306.47M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - Seeking Alpha
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - sharewise.com
How strong is ADC Therapeutics SA company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is ADC Therapeutics SA company’s growth strategyGet alerts on high-potential stock breakouts - Jammu Links News
How volatile is ADC Therapeutics SA stock compared to the marketMaximize portfolio value with expert tips - Jammu Links News
Does ADC Therapeutics SA stock perform well during market downturnsGet daily updates on top-performing stocks - Jammu Links News
Should I hold or sell ADC Therapeutics SA stock in 2025Achieve rapid growth with smart investments - Jammu Links News
What institutional investors are buying ADC Therapeutics SA stockConsistent triple-digit returns - Jammu Links News
What is the dividend policy of ADC Therapeutics SA stockUnlock exclusive trading strategies for gains - Jammu Links News
Is ADC Therapeutics SA stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
How does ADC Therapeutics SA generate profit in a changing economyLightning-fast growth - Jammu Links News
What are the latest earnings results for ADC Therapeutics SAInvest smarter with actionable trading signals - Jammu Links News
What are ADC Therapeutics SA company’s key revenue driversUnlock high-yield investment opportunities - Jammu Links News
What is the risk reward ratio of investing in ADC Therapeutics SA stockAchieve rapid capital gains with smart investing - Jammu Links News
Earnings Beat: ADC Therapeutics SA (NYSE:ADCT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - 富途牛牛
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Adc Therapeutics shares rise 11.52% after-hours after granting options to new employees. - AInvest
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - StreetInsider
ADC Therapeutics Makes Grants To New Employees Under Inducement Plan - Barchart.com
ADC Therapeutics SA expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Can volume confirm reversal in ADC Therapeutics SAReal-Time Analysis With Entry Targets In Progress - metal.it
How ADC Therapeutics SA stock performs during market volatilityTarget Return Focused Trade Insights Shared - metal.it
ADC Therapeutics SA Price Targets Raised After ReboundWeekly Watchlist of High Movers Released - metal.it
ADC Therapeutics SA Breaks Losing Streak — Is the Trend ReversingTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Neuroendocrine Tumors Clinical Trials, Companies, - openPR.com
Neuroendocrine Tumors Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli L - Barchart.com
ADC Therapeutics SA Shows Risk Reward Favoring UpsideExit Ready Momentum Stock Watchlist Expanded - metal.it
What catalysts could drive ADC Therapeutics SA stock higher in 2025Extraordinary earning power - Jammu Links News
What makes ADC Therapeutics SA stock price move sharplyHigh Return Intraday Picks - metal.it
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
0.08%
자본화:
|
볼륨(24시간):